Lexicomp Online

Wolters Kluwer

2018

Grace Jeong
grace.jeong@wolterskluwer.com

내 컴퓨터에 Lexicomp Online 바로가기 생성하기



1. 인터넷 주소창에서 Lexicomp Online 아이콘 마우스로 드래그
2. 바탕화면 혹은 작업표시줄에 갖다 놓기
3. 바로가기 생성

How to Search?

http://online.lexi.com

1. 첫 화면


Clinical Drug Information
Lexicomp®
피드백 회사 사용자 가이드 로그아웃
언어 선택
상호 작용 약물 ID 계산 Drug Comparisons Trissel's IV Compatibility 환자 교육 Formulary Monograph Service 독성학 UpToDate® 추가 임상 도구
10가지 모듈
도움말
Lexicomp Online
키워드 검색 창
다음으로 검색 제한
약물, 질환, NDC 또는 기타 키워드 입력
검색
특별 경고
특별이슈
CloZAPine: Clozapine
Delayed
BuPROPion: Chantix and Zyban Safety Review
LORazepam: Anesthetic and Sedation Drugs Safety Alert
PENTobarbital: Anesthetic and Sedation Drugs Safety Alert
Etomidate: Anesthetic and Sedation Drugs Safety Alert
추가 특별 경고
Training Videos
Quick Reference Guide
Product Updates
Important enhancements to Lexicomp® Online
New FMS interface, clinical pharmacogenomics, and more!
Explore the latest Lexicomp Online enhancements, including a redesigned interface for the Formulary Monograph Service (FMS) add-on module; new summary pharmacogenomics monographs focused on content to support clinical practice; and new drug monograph fields.
Learn More

2. 키워드 검색

1. 키워드 입력
2. Search 버튼 누르기
3. 관련된 모든 데이터베이스의 결과 나열
4. 최근 업데이트 날짜
5. 원하는 결과 선택 혹은 마우스 오버
6. 전체 하위메뉴
7. 원하는 정보 선택하면 오른쪽에서 확인 가능
8. 다른 정보로 이동하고자 할 경우, Jump to Section 선택





1) Labeled Uses 정보 제공





2) Off Uses 정보 제공



3) Doses


Navigation Tree
Expand All
Uses
Breast Cancer
AIDS-related Kaposi's Sarcoma
Ovarian Cancer
Other Uses
Dosage and Administration
Conventional Doxorubicin Hydrochloride
Liposomal Doxorubicin Hydrochloride
Conventional Doxorubicin
상황에 따른 다양한 복용정보
1
Monograph
Images
Adult Patient Education
Pediatric Patient Education
Jump to Section
Print
Dosage and Administration
Reconstitution and Administration
Doxorubicin hydrochloride conventional and PEG-stabilized liposomal for injection concentrate are administered IV. The drug is extremely irritating to tissues and, therefore, must not be given IM or subcutaneously. (See Cautions: Local Effects.)Care should be taken to avoid extravasation of the drug.
Because doxorubicin may cause adverse local dermatologic reactions, commercially available conventional and liposomal doxorubicin hydrochloride for injection concentrate, the powder for injection, and solutions of the drug must be prepared and handled cautiously and the use of latex gloves is recommended.Ref If the powder or solutions of the drug contact the skin or mucous membranes, the affected area should be immediately and thoroughly washed with soap and water.Ref Parenteral doxorubicin hydrochloride solutions should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.Ref However, because PEG-stabilized liposomal doxorubicin hydrochloride occurs as a liposomal dispersion, the for injection concentrate is not clear but rather is translucent and

4) Clinical Practice Guidelines

Navigation Tree

Expand All

Dosing: Geriatric

Dosing: Pediatric

Dosing: Renal Impairment

Dosing: Hepatic Impairment

- Uses
- Clinical Practice Guidelines
- Administration and Storage Issues
- Medication Safety Issues
- Medication Guide
- Warnings & Precautions
- Pregnancy & Lactation
- Adverse Reactions
- Interactions
- Patient & Therapy

Monograph | Images | Adult Patient Education | Pediatric Patient Education

Jump to Section | Print | He

Clinical Practice Guidelines

Atrial Fibrillation:

적응증 별로 Guideline 분류

"ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation," August 2006

"ACCF/AHA/HRS 2011 Focused Update on the Management of Patients with Atrial Fibrillation (Updating the 2006 Guideline)," January 2011

Canadian Cardiovascular Society, "Focused 2012 Update o Society Atrial Fibrillation Guidelines: Recommendation Rate/Rhythm Control," January 2012

Heart Failure:

"HFSA 2010 Comprehensive Heart Failure Practice Guideli

Prevention:

"AHA/ACCF Secondary Prevention and Risk Reduction The and Other Atherosclerotic Vascular Disease: 2011 Upd

Pulmonary Embolism:

원문 열람 가능



Canadian Journal of Cardiology 28 (2012) 125–136

Society Guidelines

Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control

Allan C. Skanes, MD, FRCPC,[a] Jeff S. Healey, MD, MSc, FRCPC,[b] John A. Cairns, MD, FRCPC,[c] Paul Dorian, MD, FRCPC,[d] Anne M. Gillis, MD, FRCPC,[e] M. Sean McMurtry, MD, PhD, FRCPC,[f] L. Brent Mitchell, MD, FRCPC,[e] Atul Verma, MD, FRCPC,[g] Stanley Nattel, MD, FRCPC,[h] and the Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee*

ABSTRACT

The Canadian Cardiovascular Society (CCS) published the complete set of 2010 Atrial Fibrillation (AF) Guidelines in the January, 2011 issue of the Canadian Journal of Cardiology. During its deliberations, the CCS Guidelines Committee engaged to a timely review of future evidence, with periodic composition of focused updates to address clinically important advances. In 2011, results were published from 3 pivotal AF trials: the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonist for Prevention of Stroke

RÉSUMÉ

La Société canadienne de cardiologie (SCC) a publié l'ensemble des lignes directrices de 2010 en matière de fibrillation auriculaire (FA) dans le numéro de janvier 2011 du Journal canadien de cardiologie. Au cours de ses discussions, le comité des lignes directrices de la SCC s'est engagé à revoir régulièrement les nouvelles données par la rédaction périodique de mises à jour ciblées portant sur les avancées cliniques importantes. En 2011, les résultats de 3 essais pivots sur la FA ont été publiés : le ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor

The development of the 2010 Canadian Cardiovascular Society (CCS) Atrial Fibrillation (AF) Guidelines included a commitment to a timely review of emerging evidence, with the periodic production of focused updates to address clinically important advances. In 2011, results were published from 3 pivotal AF trials: the Rivaroxaban Once Daily Oral Di-

Received for publication January 29, 2012. Accepted January 30, 2012.

*A complete list of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee primary and secondary panels is available in Supplemental Appendix S1.

Correspondence author: Dr Allan Skanes, Arrhythmia Service, University of

sents the consensus of a Canadian panel comprised of multidisciplinary experts on this topic with a mandate to formulate disease-specific recommendations. These recommendations are aimed to provide a reasonable and practical approach to care for specialists and allied health professionals obliged with the duty of bestowing optimal care to patients and families, and can be subject to

5) Medication Safety Issues

Medication Safety Issues

1 ▼ **Sound-alike/look-alike issues:** 발음이 유사하여 주의해야 하는 약품

FLUoxetine may be confused with DULoxetine, famotidine, Feldene, fluconazole, fluvastatin, fluvoxaMINE, fosinopril, furosemide, Loxitane [DSC], PARoxetine, thiothixene, vortioxetine

PROzac may be confused with Paxil, Prelone, PriLOSEC, Prograf, Proscar, ProSom, Provera

Sarafem may be confused with Serophene

2 ▼ **BEERS Criteria medication:** Beers Criteria 2012 제공

This drug may be potentially inappropriate for use in geriatric patients with a history of falls or fractures (Quality of evidence - high [moderate for SIADH]; Strength of recommendation - strong).

3 ▼ **International issues:** International Issues!

Reneuron [Spain] may be confused with Remeron brand name for mirtazapine [U.S., Canada, and multiple international markets]

6) 참고문헌 제공


Navigation Tree
Expand All
Response
Drugs or Supplements Decreasing Anticoagulant Response
Specific Drugs
Pharmacokinetics
Absorption
Distribution
Elimination
Stability
Actions
Advice to Patients
Preparations
1 References
Copyright
Monograph
Images
Adult Patient Education
Pediatric Patient Education
Jump to Section
Print
Help
2 References
인용한 전체 Reference
Only references cited for selected revisions after 1984 are available electronically.
Koch-Weser J, Sellers EM. Drug interactions with coumarin anticoagulants (Second of two parts). New Engl J Med. 1971; 285:547-558 [PubMed 4397794]
3
National Institutes of Health Consensus Development Conference. Prevention of venous thrombosis and pulmonary embolism. JAMA. 1986; 256:744-9. [PubMed 3723773]
Hirsch J. Therapeutic range for the control of oral anticoagulant therapy. Arch Intern Med. 1985; 145:1187-8. [IDIS 201237] [PubMed 4015265]
Suchman AL, Griner PF. Diagnostic uses of the activated partial thromboplastin time and prothrombin time. Ann Intern Med. 1986; 104:810-6. [PubMed 3706933]
PubMed로 연결
PubMed.gov
US National Library of Medicine
National Institutes of Health
PubMed
Search
Advanced
Help
Display Settings: Abstract
Send to:
NEJM FULL TEXT
N Engl J Med. 1971 Sep 2;285(10):547-58.
Drug interactions with coumarin anticoagulants. 2.
Weser JK, Sellers E.
PMID: 4397794 [PubMed - indexed for MEDLINE]
Publication Types, MeSH Terms, Substances
LinkOut - more resources
Save items
Add to Favorites
Related citations in PubMed
Drug interactions with anticoagulants. [JAMA. 1970]

7) 이미지 및 한글 복약지도문 제공

Clinical Drug Information



이미지 제공



영문 환자복약지도문



한글 환자복약지도문



8) 16가지 데이터베이스별로 특성화된 정보 제공



1 Briggs Drugs in Pregnancy and Lactation



Briggs Drugs in Pregnancy and Lactation 제공



연쇄구균성 인두염을 앓고 있는 생후 1주일 된 신생아기에게 Ampicillin을 처방하려고 합니다.
처방 양을 어떻게 해야 하나요?

Lexicomp

Feedback Corporate User Guide Logout

1 ampicillin Search Limit search to Recent Documents

Interactions | Drug I.D. | Calculators | I.V. Compatibility | Patient Education | Toxicology | More Clinical Tools

Search Results: monograph name beginning with "ampicillin"

All Results

Filter Results Print Hel

Pediatric and Neonatal Lexi-D

2 **Ampicillin** *Updated 8/28/12*

Ampicillin and Sulbactam

AHFS Essentials (Adu

Ampicillin Sodium and Sulbactan

Ampicillin, Ampicillin Sodium, Ampicillin ydrate

AHFS DI (Adult and Pediatric)

Ampicillin Sodium and Sulbactam Sodium

Ampicillin, Ampicillin Sodium, Ampicillin Trihydrate

Martindale: The Complete Drug Reference

Ampicillin *Updated 6/29/12*

Ampicillin and Probenecid for Oral Suspension USP 35

3 마우스오버 시, 하위메뉴 표기

Available Sections

Additional Information
Administration
Adverse Reactions
Allergy and Idiosyncratic Reactions
Brand Names: Canada
Breast-Feeding Considerations
Contraindications
Dosage Forms
4 Dosing: Neonatal
Dosing: Usual
Drug Interactions
Drug Interactions:
Metabolism/Transport Effects
Food Interactions

5

Bacteremia, Group B streptococcal (presumed or proven) (*Red Book*, 2012): **Note:** Treatm
days: I.M., I.V.:

Body weight ≤2 kg:

PNA ≤7 days: 100 mg/kg/dose every 12 hours

PNA 8-28 days: 50 mg/kg/dose every 8 hours

Body weight >2 kg:

PNA ≤7 days: 100 mg/kg/dose every 12 hours or 50 mg/kg/dose every 8 hours

PNA 8-28 days: 50 mg/kg/dose every 6 hours

Meningitis, Group B streptococcal: I.V.:

PNA ≤7 days: 50-100 mg/kg/dose every 8 hours for at least 14 days if uncomplicated; so
(*Red Book*, 2012; Tunkel, 2004)

PNA >7 days: 50-75 mg/kg/dose every 6 hours for at least 14 days if uncomplicated; some
Book, 2012; Tunkel, 2004)

황색포도알균의 카바페넴의 적정한 치료 시기와 Cross-Reactivity에 관하여 알고 싶습니다.



Tremor를 유발할 수 있는 약제에 대하여 검색하고 싶습니다.



REMS Components Medication

Medication Guide An FDA-appro
which is available with the product informa
http://www.fda.gov/downloads/Drugs/Drug
dispensed with this medication. A Warnin
of hypersensitivity), which is available with
also be dispensed with this medication fo
prescription and r

Contraindic
of the formulation
hypersensitivity to
to severe hepatic

MEDICATION GUIDE REMS

NDA 020-977 Ziagen® (abacavir sulfate) T
NDA 020-978 Ziagen® (abacavir sulfate) Oral

Nucleoside Reverse Transcriptase Inhibitors (

ViiV Healthcare Company
5 Moore Drive
Research Triangle Park, NC 27709
1-877-844-8872
Contact: Susan L. Watts, Ph.D.
Global Regulatory Affairs
GlaxoSmithKline
1-919-483-5540

ABBREVIATIONS, ACRONYMS, AND SYMBOLS
Lexi-Drugs Online

Abbreviations Which May Be Used in This Reference

Abbreviation	Meaning
5-HT	5-hydroxytryptamine
AAP	American Academy of Pediatrics
	lood gases
	l body weight
	n Academy of Clinical Toxicology

Lexi-Drugs
Generic Names
U.S. Brand Names
Canadian Brand Names
1 Charts/Special Topics
Changed Last 7 Days
Pharmacologic/Therapeutic Category
4 REMS
5 Prescribing and Access Restrictions
6 Black Box Warnings
Special Alerts

Acetaminophen
Lexi-Drugs Online

Images | Interactions | Adult Patient Ed | English | Pedi

Jump To Field (Select Field Name)

Special Alerts

Acetaminophen: Change in Maximum Content of Prescription Products and Labeling Changes - January 2011

The Food and Drug Administration (FDA) is asking manufacturers to limit the strength of acetaminophen in **prescription** products to 325 mg per dosage unit. Drug manufacturers will have until January 14, 2014 to comply with the FDA's request. The dosing instructions of prescription acetaminophen products will not change. For example, the instructions of 1 -2 tablets every 4-6 hours for a combination product of acetaminophen 500 mg with an opioid can still be used for a combination product of acetaminophen 325 mg with an opioid.

ctions | Adult Patient Ed | English

Jump To Field (Select Field Name)

ALERT: U.S. Boxed Warning The FDA-approve
includes a boxed warning. See Warnings/Precautions sectio
concise summary of this information. For verbatim wording
warning, consult the product labeling or www.fda.gov.

Pronunciation (a BAK a veer)

U.S. Brand Names Ziagen®

Canadian Brand Names Ziagen®

Searching Tip

1. 도표 및 특수 토픽
2. 신규 의약품정보
3. 치료 관련 카테고리
4. Risk of Evaluation & Mitigation Strategy : 의약품 위해성 완화전략으로 미국 FDA와 유럽 EMA 등 의약품 규제기관이 시행하고 있는 선진국형 의약품 안전성 관리 전략 (우리나라도 도입 준비 중)
5. Black Bow Warnings: 미국의 FDA에서 제공하는 주의사항
6. Special Alerts: 임상의들이 알고 있어야 할 새로운 소식 및 주의사항 제공

3. Drug Interaction

- Lexi-Interact는 단지 Interaction과 심각도 정도만 제공하는 것이 아니라, 발병 혹은 심각도에 영향을 미칠 수 있는 모든 요인을 확인 및 리뷰하여 정보를 제공하고 있음. (Ex. Dependency of Dosing, Routes, etc.)



- 의약품 뿐 아니라, Natural Products / Food 및 다른 성분들과도 조합 가능

- Facts and Comparisons에서 제공하는 Drug Interaction와 통합하여, Drug-Drug Interaction 뿐 아니라, Drug-Allergy / Drug-Diseases와 관련된 상호작용 정보도 제공

1. 상단의 Interactions 선택
2. 약품명, 성분명, 음식명 등 키워드 입력 후 선택
3. 환자 알러지 검색 후 입력
4. Interaction 분석하고자 하는 약품목록
5. 분석 선택
6. 상호작용, 알러지, 중복처방 결과가 A,B,C,D,X의 정도와 함께 제공
7. 의약품명 선택 시, 상세정보 제공
8. 참고문헌 제공

Warfarin과 상호작용이 있는 전체 약품 목록을 알고싶어요.





1. Selected Items 목록에서 Warfrin 선택
2. 혹은 키워드에서 Warfarin만 검색 후 Analyze
3. Warfarin과 상호작용 있는 모든 약품 리스트
4. Dose, Indications 등 상황에 따라 Interaction이 다른 경우, 표기됨
5. Lexi-Drugs 내에 Interaction 하위메뉴에도 동일한 정보 제공
6. Open Lexi-interact 선택 시, Interaction 모듈로 이동

4. Drug ID

상호 작용 | 약물 ID | 계산 | 정맥 주사 적합성 | 환자 교육 | 독성학 | Facts & Comparisons® | 추가 임상 도구

약물 I.D.

검색 조건

Imprint Side 1

1 C

Imprint Side 2

200

제형

Capsule

모양

oblong

색상

-- 선택 --

x white

2 검색 지우기

검색 결과

도움

검색 결과

검색 결과: 6

이미지를 클릭하여 인쇄 가능한 세부 정보 확인

세 이미지, 제공

정렬 기준: 일반명

1/1페이지

Partial Match Results

이미지	일반명			제형	강도	모양	색상
	Acyclovir (Systemic)			Capsule	200 mg	oblong	light blue, white
	Acyclovir (Systemic)		AVPAK	200 CTI 111	Capsule	200 mg	oblong	light blue, white

3

검색 결과 | Acyclovir (Systemic)

Acyclovir (Systemic)

Lexicomp Online 검색

Scale = 1/8" or 3.175mm"

NDC 11	42291010701
NDC 11	42291010750
Labeler	AVKARE
Generic Name	Acyclovir (Systemic)
Strength Field Collection	200 mg

5. Calculators

1. 화면 상단의 Calculators 선택
2. 키워드로 Calculator 검색
3. 카테고리 별 검색
4. 알파벳 순 찾기
5. 원하는 Calculator 선택
6. 숫자 입력
7. 입력해야 하는 숫자 범위 제공
8. Calculator 선택
9. 자동으로 계산됨
10. Calculator 관련 추가 부가정보







6. Drug Comparisons

- 두 가지의 의약품 비교 테이블 제작 도구
- 1) Data View: 한 눈에 보기 쉽게 요약된 테이블 제작, 링크 클릭 시, 상세정보 제공
  2) Monograph View: 모든 정보가 서술된 테이블 제작
- 약품 분류, 상호작용, 주의사항, 부작용, 과다 복용 등 다양한 하위메뉴의 비교테이블 제작 가능
- FDA 제공 Severity 정보 등 유용한 정보 제공
- 최대 4개 의약품 비교 제작 가능

1) Data View


Lexicomp
약물, 질환, NDC 또는 기타 키워드 입력
검색
다음으로 검색 제한
언어 선택
최근 문서
상호 작용
약물 ID
Drug Comparisons
Trissel's IV Compatibility
환자 교육
Formulary Monograph Service
독성학
UpToDate®
추가 임상 도구
Data View
Monograph View
Data View
Selected Drugs
검색
도움말
약물
Atorvastatin Calcium Oral
Lipitor Oral
Simvastatin Oral
검색
statin
검색
Statins Depletion Oral
Statins Support Oral
The Data Compare tool allows the user to compare up to 4 drugs using th
Available Sections
Adverse Effects
Indications
Drug-Pregnancy
Drug-Lactation
Contraindications/Precautions
Drug-Drug Interactions
Drug-Food Interactions
Drug-Alcohol Interactions
Compare
지우기
약관 // 부인
© 2017 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. A
검색
Results
섹션으로 이동
인쇄
Adverse Effects
Indications
Drug-Pregnancy
Description
Atorvastatin Calcium Oral
Lipitor Oral
Simvastatin Oral
Statins Depletion Oral
Pregnancy
Contraindicated
Contraindicated
Contraindicated
Drug-Lactation
Description
Atorvastatin Calcium Oral
Lipitor Oral
Simvastatin Oral
Statins Depletion Oral
Lactation
Contraindicated
Contraindicated
Contraindicated
Contraindications/Precautions
Description
Atorvastatin Calcium Oral
Lipitor Oral
Simvastatin Oral
Statins Depletion Oral
All Patient Populations
Child-Bearing Aged Females
Critically Ill Patients
Geriatric Patients
Patients Less Than 10 Years
Child-Bearing Aged Females
Critically Ill Patients
Geriatric Patients
Patients Less Than 10 Years
Child-Bearing Aged Females
Geriatric Patients
Patients Less Than 10 Years

2) Monograph View



6. Trissel's IV Compatibility

- 정맥주사 혼합 적합 여부 확인 가능한 데이터베이스
- Y-Site / Admixture / Syringe에 해당하는 Compatibility 정보 제공
- 한 눈에 보기 쉽게 테이블형태로 제공되며, 상세한 정보도 제공
- Lexicomp에서 제공되는 Trissel의 장점
  - Solution과의 Compatibility도 확인 가능
  - Storage 등 해당 의약품의 특성 제공
  - Y-Site / Admixture / Syringe의 비교 테이블을 한 페이지에 제공



1. 화면 상단의 Trissel's 선택
2. 약품명 입력
3. 수액 등 Solutions 입력
4. 입력한 주사제 및 수액 확인
5. 분석
6. Y-Site, Admixture, Syringe의 Compatibility 정보를 한 테이블에서 볼 수 있음
7. 원하는 정보 아이콘 선택 시, 상세정보 제공
8. Study Design 및 결론에 관한 상세정보 제공

Acetaminophen과 관련된 전체 I.V. Compatibility 정보를 확인 할 수 없나요?

1. 약물 검색창에서 주사제 입력
2. 왼쪽 창에서 주사제명 클릭
3. 오른쪽 결과 제공

Trissel's™ 2 Clinical Pharmaceutics Database (created by La

선택된 항목

Click on the drug name to view compatibility results for a single drug or for a drug properties monograph.

2

약물

- Acetaminophen
- Epinephrine hydrochloride
- Rocephin [Ceftriaxone sodium]
- Vancomycin HCl [Vancomycin hydrochloride]

용액

- D5W (Dextrose 5% in Water)

분석 지우기

검색 | Acetaminophen - IV Compatibilities | 적합성 차트 | Acetaminophen - 속성

All Methods

3

Acetaminophen - IV Compatibilities

C 이 방법에 대한 적합성을 나타냅니다.
U 이 방법의 경우 불확실하거나 가변적입니다.
I 이 방법에 대한 부적합성을 나타냅니다.

Drugs

Y-Site Compatibility

- I Acyclovir
- I Chlorpromazine hydrochloride
- I Diazepam
- U Ketoprofen
- C Buprenorphine hydrochloride
- C Butorphanol tartrate
- C Cefoxitin
- C Ceftriaxone sodium
- C Cimetidine hydrochloride
- C Clindamycin phosphate
- C Defibrotide

Acetaminophen의 안전성과 저장방법에 대하여 알고 싶어요.

ug Information

1. 약물 검색창에서 주사제 입력
2. 왼쪽 창에서 주사제명 클릭
3. 오른쪽 결과화면에서 Acetaminophen-속성 클릭
4. 속성 제공

Trissel's™ 2 Clinical Pharmaceutics Database (created by La

선택된 항목

Click on the drug name to view compatibility results for a single drug or for a drug properties monograph.

2

약물
- Acetaminophen
- Epinephrine hydrochloride
- Rocephin [Ceftriaxone sodium]
- Vancomycin HCl [Vancomycin hydrochloride]

용액
- D5W (Dextrose 5% in Water)

분석 지우기

검색 | Acetaminophen - IV Compatibilities | 적합성 차트 | 3 Acetaminophen - 속성

All Methods

Acetaminophen - IV Compatibilities

C 이 방법에 대한 적합성을 나타냅니다.
U 이 방법의 경우 불확실하거나 가변적입니다.
I 이 방법에 대한 부적합성을 나타냅니다.

Drugs

Y-Site Compatibility

- I Acyclovir
- I Chlorpromazine hydrochloride
- I Diazepam
- U Ketoprofen
- C Buprenorphine hydrochloride
- C Butorphanol tartrate
- C Cefoxitin
- C Ceftriaxone sodium
- C Cimetidine hydrochloride
- C Clindamycin phosphate
- C Defibrotide

4

Acetaminophen

Trade Name(s)

Ofirmev

Formulation

Provided as a sterile, clear, colorless, nonpyrogenic, isotonic solution in single-use vials. Each 1 mL contains acetaminophen (paracetamol) 10 mg, mannitol 38.5 mg, cysteine hydrochloride 0.25 mg, and dibasic sodium phosphate 0.104 mg. Sodium hydroxide and/or hydrochloric acid may have been added during manufacturing to adjust pH.

NOTE: For product information outside of the US, refer to the manufacturer's labeling. Ref

Reconstitution

For IV infusion only. Administer undiluted over 15 minutes. Use within 6 hours of opening vial or transferring to another containe

For doses less than 1,000 mg (less than 50 kg): Withdraw appropriate dose from vial and place into separate empty, sterile container prior to administration. Small volume pediatric doses (up to 600 mg [60 mL]) may be placed in a syringe and infused o 15 minutes via syringe pump.

For 1,000 mg doses (50 kg or more): Insert vented IV set through vial stopper.

NOTE: For product information outside of the US, refer to the manufacturer's labeling. Ref

Stability

Infusion Solutions:
The manufacturer recommends using within 6 hours of opening vial or transferring to another container. Discard any unused

7. 환자교육

- 현재 1,973종의 환자 복약지도문을 제공하고 있으며, 이 중 일부를 한글 포함한 19개 언어로 제공 하고 있음.
- 각 의약품의 Monograph마다 환자 복약지도문을 확인할 수도 있고, Patient Education 모듈이 있어 여러 의약품의 환자 복약지도문을 만들 수도 있다.
- 성인 / 소아로 구분되어 제공됨
- 2012년 말, Joint Commission Standard에 부합하는 복약지도문 추가; 2,400개 이상의 복약지도문 이용 가능
  - Conditions: 1,300
  - Procedures: 400
  - Discharge Summaries: 600
  - Wellness Documents: 100
- 가장 많이 활용되는 환자복약지도문 222가지는 한글로도 제공

1) 한 가지 의약품의 복약지도문 출력 및 편집



2) 두 개 이상의 복약지도문 제작

1. 화면 상단의 Patient Education 선택
2. 복약지도문 출력하고자하는 약품명 검색
3. 성인 및 소아 중 선택
4. 언어 변경
5. Store Current Packet 선택하여 새로운 폴더 생성
6. 폴더명 입력
7. 저장
8. Store에서 저장한 폴더 불러오기
9. 복약지도문 출력 가능



8. Formulary Monograph Service

- 의약품의 연구정보 제공
- 의약품 관련 비교효능 정보를 포함한 다양한 연구정보 요약하여 제공
- 최근에 발표되었거나, 연구중인 약물 관련 임상실험에 관한 상세한 정보 제공
- 1,000가지 이상의 의약품에 관한 P&T 정보 제공
- 효과를 증진시킬 수 있는 연구에 관한 과거 자료도 제공
- 최근 출시된 신약 및 Clinical Trial Phase III의 연구 자료 제공하여, 신약이 기존 의약품과 어떤 차이가 있는지 보여주는 비교 차트정보 제공
- P&T Formulary Reviews / P&T Summary Reviews / Drug Use Evaluation / New Drug Reviews 4가지 기능 제공

Warfarin은 International Normalized Ratio 수치 유지를 위한 정기적인 혈액검사, 용량 조절, 출혈 위험도, 음식이나 약제와의 상호작용과 같은 많은 제한점을 갖고 있습니다. 그래서 새로운 경구용 항응고제의 Dabigatran이 연구되고 있는데, Warfarin과 Dabigatran의 비교 효능정보를 알고 싶습니다.

상호 작용 | 약물 ID | 계산 | Drug Comparisons | Trissel's IV Compatibility | 환자 교육 | Formulary Monograph Service | 독성학 | UpToDate® | 추가 임상 도구

1 P&T Formulary Reviews
P&T Summary Reviews
Drug Use Evaluations
New Drug Reviews

사용 가능한 색인
P and T Formulary Reviews
Generic Names
U.S. Brand Names
Pharmacologic/Therapeutic Category

P and T Formulary Reviews

인쇄 | 도움말

Generic Names

Generic Names 색인 탐색

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

2 DABIGATRAN ETEXILATE MESYLATE *Updated 10/6/16*

3 **DABIGATRAN ETEXILATE MESYLATE** (P and T Formulary Reviews)

탐색 트리

모두 확장

- Brand Names: U.S.
- Evaluation
- Proprietary Name
- Approval Rating
- Therapeutic Class
- Similar Drugs
- Sound / Look-Alike Names
- Indications
- Clinical Pharmacology
- Pharmacokinetics
- ▸ Comparative Efficacy
- ▸ Contraindications, Warnings

공정서 | 이미지 | 성인 환자 교육

섹션으로 이동 | 인쇄 | 도움말

DABIGATRAN ETEXILATE MESYLATE *(P and T Formul*

Brand Names: U.S. Pradaxa

Evaluation

Updated Evaluation

Proprietary Name

Pradaxa (Boehringer Ingelheim)

Approval Rating

1S

Therapeutic Class Direct Thrombin Inhibitors

Similar Drugs

Comparative Efficacy

Atrial fibrillation — stroke prevention

Dabigatran etexilate was assessed in a randomiz
fibrillation. Patients received dabigatran 50, 150,
or open-label warfarin dosed to achieve an INR
receiving the 50 mg dose. Major bleeding occurre
bleeding events occurred more frequently (22% and 18%, respectively) in the 300 mg group ($P = 0.0002$) and 150 mg group ($P = 0.01$) than in the 50 mg group (7%).[Ref] In a long-term extension of this study (mean follow-up, 29 months), 361 patients continued therapy. The warfarin arm was discontinued and patients in the dabigatran 50 mg group were switched to 150 mg once daily. Because of the higher frequency of major bleeding events in the 300 mg group and thromboembolic events in the 150 mg once-daily group, those patients were ultimately switched to dosages of 300 mg once daily or 150 mg twice daily. Results are summarized in Table 1.[Ref]

Study Design 요약

Table 1. Long-Term Result

	50 mgTwice Daily	150 mg(			
Subjects treated	105				
Total exposure (patient-years)	23.51	58.52	198.68	683.88	82.01
Major bleeds	0%	5.1%	2.5%	4.2%	12.2%
Stroke and systemic thromboembolism	12.8%	5.1%	2.5%	1%	1.2%
TIA[a]	0%	0%	0%	0.1%	0%

[a]TIA = transient ischemic attack.

연구결과 표 제공

8. 독성학

Information

가정용품 중 Antifreeze의 성분과, Antifreeze를 섭취하였을 때, 응급 처치방법의 기준에 대해서 알고 싶습니다 .

1. 화면 상단의 Toxicology 선택
2. Toxicology의 독극물 식별, 계산정보, Compatibility 제공
3. 다시 Lexicomp Online으로 돌아가고자 할 경우, Leave Toxicology Mode 선택
4. 키워드 검색
5. 카테고리별로 검색 가능
6. Household 데이터베이스에서 Pennzoil Antifreeze 선택

7. Ingredient에서 성분정보 확인
8. Glycol 선택하여 Treatment에서 응급처치방법 확인



9. Lexicomp Online에서 UpToDate 검색하기

1. 화면 상단의 UpToDate 메뉴 선택
2. UpToDate 검색 박스에 검색어 입력 후 검색
3. 팝업창으로 UpToDate 검색결과 제공
4. UpToDate 비구독기관은 UpToDate 메인 화면으로 이동



10. 기타임상링크

Clinical Links

- New Drugs
- ASHP Drug Shortages
- ISMP (Institute for Safe Medication Practices)
- National Library of Medicine
- Orange Book
- FDA Recalls
- Dangerous Abbreviations
- Canadian Drug Shortages
- Ontario Drug Benefit
- Switch Rx
- ISMP Canada
- ISMP Canada Safety Bulletins
- Quebec's Government website
- APES Quebec (information associated with Pallative Care)
- Health Canada-Natural Products
- Needy Meds (Information on Manufacture Patient Assistance Programs)
- Vaccine Information Statements (Centers for Disease Control)

2



Thank you!